ClinicalTrials.Veeva

Find clinical trials for Eczema in Seattle, WA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Dermatitis
Atopic Dermatitis
Dyssomnias
Food Hypersensitivity
Hypersensitivity
Parasomnias
Psoriasis

Eczema trials near Seattle, WA, USA:

Phase 2a Study of Efficacy and Safety of OpSCF in Moderate to Severe Atopic Dermatitis

the treatment of adults with moderate to severe Atopic Dermatitis (Eczema). OpSCF will be compared to a placebo.OpSCF or placebo will be adm...

Enrolling
Atopic Dermatitis
Biological: OpSCF
Biological: Placebo

Phase 2

Opsidio, LLC

Bellevue, Washington, United States and 21 other locations

This is a phase IIa, randomized, double-blind, placebo-controlled, multi-center proof-of-concept (POC) study in subjects with moderate to severe Atop...

Enrolling
Atopic Dermatitis
Drug: ADX-914
Drug: Placebo

Phase 2

Q32 Bio

Seattle, Washington, United States and 39 other locations

This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of subcutaneous lirentelimab (...

Active, not recruiting
Atopic Dermatitis
Drug: AK002
Other: Placebo

Phase 2

Allakos

Seattle, Washington, United States and 54 other locations

The primary objective of the study is to assess the long-term safety of dupilumab in pediatric participants with AD.The secondary objectives of the s...

Active, not recruiting
Atopic Dermatitis
Drug: Dupilumab

Phase 3

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Seattle, Washington, United States and 83 other locations

This study is being conducted to establish the efficacy of ruxolitinib cream in participants with moderate AD who had an inadequate response to, or a...

Enrolling
Atopic Dermatitis
Drug: Ruxolitinib Cream
Drug: Vehicle Cream

Phase 3

Incyte
Incyte

Mill Creek, Washington, United States and 105 other locations

B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...

Active, not recruiting
Dermatitis, Atopic
Drug: Abrocitinib 100 mg
Drug: Placebo

Phase 3

Pfizer
Pfizer

Seattle, Washington, United States and 560 other locations

This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.

Active, not recruiting
Atopic Dermatitis
Biological: Lebrikizumab

Phase 3

Lilly
Lilly

Seattle, Washington, United States and 318 other locations

The objective of this study is to assess the efficacy and safety of upadacitinib combined with topical corticosteroids (TCS) for the treatment of ado...

Invitation-only
Atopic Dermatitis
Drug: Placebo
Drug: Upadacitinib

Phase 3

AbbVie
AbbVie

Seattle, Washington, United States and 192 other locations

The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy treatment.

Enrolling
Atopic Dermatitis
Drug: Rocatinlimab
Drug: Placebo

Phase 3

Amgen
Amgen

Mill Creek, Washington, United States and 201 other locations

The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy and combination therapy treatment in adolescent subje...

Enrolling
Atopic Dermatitis
Drug: Placebo
Drug: Rocatinlimab

Phase 3

Amgen
Amgen

Bellevue, Washington, United States of America and 219 other locations

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems